Tag: disease

Charlotte, NC, June 23, 2026 (GLOBE NEWSWIRE) -- Viscosoft has earned the New York Times Wirecutter designation for best memory foam mattress topper for the third consecutive year. The recognition applies to the Select High Density Mattress Topper, the company's flagship product and one of the best-selling mattress toppers on Amazon. The brand has now held the designation for three consecutive years.

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on...

Nura Bio announced the completion of a Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and...

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Following the startup's first FDA 510 (k) clearance for its contactless pulse rate monitoring, PanopticAI has now secured a second one for respiratory rate...

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 19, 2026 /CNW/ - Light AI Inc. ("Light AI"...

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Surgical Devices Market is projected to grow from about USD 188.74 billion...

Emilie Korchak from UConn Health was among 10 rare disease researchers awarded a grant at Uplifting Athletes' Young Investigator Draft on Jan. 31 at...

FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today...

EAACI Congress 2026 concluded in Istanbul, welcoming 7,429 delegates from 110 countries and marking the start of Mohamed Shamji's Presidency.

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).